<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The aim of the study was to examine the effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (PIO), a peroxisome proliferator-activated receptor (PPAR)-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi>, and <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> (FENO), a PPAR-alpha <z:chebi fb="4" ids="48705">agonist</z:chebi>, as monotherapy and in combination on <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>SUBJECTS AND METHODS: Fifteen type 2 diabetic patients received FENO (n = 8) or PIO (n = 7) for 3 months, followed by the addition of the other agent for 3 months in an open-label study </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects received a 4 h hyperinsulinaemic-euglycaemic clamp and a hepatic fat content measurement at 0, 3 and 6 months </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Following PIO, fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) (p &lt; 0.05) and HbA(1c) (p &lt; 0.01) decreased, while plasma adiponectin (AD) (5.5 +/- 0.9 to 13.8 +/- 3.5 microg/ml [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>], p &lt; 0.03) and the rate of insulin-stimulated total-body <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal (R (d)) (23.8 +/- 3.8 to 40.5 +/- 4.4 micromol kg(-1) min(-1), p &lt; 0.005) increased </plain></SENT>
<SENT sid="4" pm="."><plain>After FENO, FPG, HbA(1c), AD and R (d) did not change </plain></SENT>
<SENT sid="5" pm="."><plain>PIO reduced fasting NEFA (784 +/- 53 to 546 +/- 43 micromol/l, p &lt; 0.05), triacylglycerol (2.12 +/- 0.28 to 1.61 +/- 0.22 mmol/l, p &lt; 0.05) and hepatic fat content (20.4 +/- 4.8 to 10.2 +/- 2.5%, p &lt; 0.02) </plain></SENT>
<SENT sid="6" pm="."><plain>Following FENO, fasting NEFA and hepatic fat content did not change, while triacylglycerol decreased (2.20 +/- 0.14 to 1.59 +/- 0.13 mmol/l, p &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>Addition of FENO to PIO had no effect on R (d), FPG, HbA(1c), NEFA, hepatic fat content or AD, but triacylglycerol decreased (1.61 +/- 0.22 to 1.00 +/- 0.15 mmol/l, p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Addition of PIO to FENO increased R (d) (24.9 +/- 4.4 to 36.1 +/- 2.2 micromol kg(-1) min(-1), p &lt; 0.005) and AD (4.1 +/- 0.8 to 13.1 +/- 2.5 microg/ml, p &lt; 0.005) and reduced FPG (p &lt; 0.05), HbA(1c) (p &lt; 0.05), NEFA (p &lt; 0.01), hepatic fat content (18.3 +/- 3.1 to 13.5 +/- 2.1%, p &lt; 0.03) and triacylglycerol (1.59 +/- 0.13 to 0.96 +/- 0.9 mmol/l, p &lt; 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>Muscle <z:chebi fb="3" ids="16335">adenosine</z:chebi> 5'-monophosphate-activated protein kinase (AMPK) activity did not change following FENO; following the addition of PIO, muscle AMPK activity increased significantly (phosphorylated AMPK:total AMPK ratio 1.2 +/- 0.2 to 2.2 +/- 0.3, p &lt; 0.01) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: We conclude that PPAR-alpha therapy has no effect on NEFA or <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism and that addition of a PPAR-alpha <z:chebi fb="4" ids="48705">agonist</z:chebi> to a PPAR-gamma agent causes a further decrease in plasma triacylglycerol, but has no effect on NEFA or <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
</text></document>